ArticleInfection and drug resistance2026
Comparative Analysis of Metagenomic Next-Generation Sequencing and Conventional Culture for Pathogen Detection in 218 Patients with Pulmonary Infectious Diseases: A Retrospective Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metagenomic next-generation sequencing (mNGS) is a promising technique, but comparative studies of mNGS and culture across different pulmonary diseases are limited. Methods: We retrospectively analyzed data from 218 patients who underwent BALF mNGS testing between November 2021 and April 2025, and patients were categorized into pneumonia, bronchiectasis, NTM, tuberculosis, and other groups based on discharge diagnoses. We compared detection rates, pathogen spectra, co-infection rates, and special pathogen distributions between mNGS and culture. We also assessed concordance (Kappa) and complementary rates. Results: The overall positive detection rate of mNGS was significantly higher than that of culture (95.4% vs 67.4%, P<0.001). The overall concordance rate was 71.1%, with a Kappa of 0.42. mNGS additionally detected pathogens in 84 cases (38.5%), primarily viruses (38), Nocardia (8), NTM (15), fungi (45), and Legionella (4). Culture additionally detected 23 cases (10.6%). Co-infection was detected by mNGS in 118 cases (54.1%), far higher than culture (42 cases, 19.3%, P<0.001). The bronchiectasis group had significantly higher detection of Conclusion: mNGS provides a higher detection rate than culture in this cohort, particularly for special pathogens, and is complementary to culture. Pathogen profiles varied across disease types; however, the clinical benefit of mNGS-guided therapy remains to be evaluated in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.